tuvusertib + lartesertib

**Tuvusertib + lartesertib** is a combination of two investigational small molecule inhibitors targeting the DNA damage response pathway for oncology indications. Tuvusertib (M1774) is a potent, selective orally administered inhibitor of Ataxia Telangiectasia and Rad3-related (ATR) protein kinase, which plays a central role in DNA damage sensing and repair. Lartesertib (M4076) is an inhibitor of Ataxia Telangiectasia Mutated (ATM) protein kinase, another key regulator of cellular response to DNA damage. The combination is designed to exploit synthetic lethality by simultaneously inhibiting ATR and ATM kinases, potentially enhancing antitumor activity by impairing DNA repair in cancer cells and increasing genomic instability. The combination is currently being investigated in advanced solid tumors and epithelial ovarian cancer, particularly in patients with BRCA mutations and/or homologous recombination deficiency (HRD) who have progressed on PARP inhibitor therapy[1][2][3][5][7].